Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief Commercial Officer | May 02, 2024 | May 06, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 02, 2024 · Filed May 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,767 |
Ending reported balance
After 2024-05-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 71,767 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-05-02 · Sale · Disposed 5,000 · Balance 66,767 F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
F2: Trade made pursuant to a 10b5-1 plan executed on April 13, 2023.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,277 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 4,277 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2021 Filed Sep 24, 2021 22:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,665 | $17.78 | $65,163.70 |
DisclosureSEC source: 0001209191-21-057702 · doc4.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,510 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a "sell to cover" transaction. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057702 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,175 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 22, 2021. Read SEC document |
| April 30, 2021 Filed Oct 28, 2021 23:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 342 | $62.41 | $21,343.19 |
DisclosureSEC source: 0001567619-21-018936 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,592 F1 · date: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,537 | $78.81 | $121,130.97 |
DisclosureSEC source: 0001567619-21-007870 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,250 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 18:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,652 | $74.79 | $123,553.08 |
DisclosureSEC source: 0001567619-21-007368 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,787 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 21:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,181 | $76.30 | $90,110.30 |
DisclosureSEC source: 0001567619-21-007083 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,439 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 00:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,513 | $78.52 | $118,800.76 |
DisclosureSEC source: 0001567619-21-006814 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,620 Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 01:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,308 | $77.99 | $102,010.92 |
DisclosureSEC source: 0001567619-21-006721 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,133 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 01:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,287 | $77.21 | $99,369.27 |
DisclosureSEC source: 0001567619-21-006549 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,441 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 26,400 | $0.00 Strike: $78.39 | $0.00 |
DisclosureSEC source: 0001567619-21-006549 · doc1.xml · derivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2031-03-14 F2 · date: Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,273 | $78.39 | $413,350.47 |
DisclosureSEC source: 0001567619-21-006549 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,728 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006549 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,001 F1 · price: Restricted stock units granted on March 15, 2021. Price not applicable. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 23:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,121 | $79.91 | $169,489.11 |
DisclosureSEC source: 0001567619-20-017890 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,281 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,250 | $17.25 | $56,062.50 |
DisclosureSEC source: 0001209191-20-052511 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,975 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.06 to $17.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $18.91 | $0.00 |
DisclosureSEC source: 0001209191-20-052039 · doc4.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052039 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,225 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:10 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001209191-20-052150 · doc4a.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:10 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052150 · doc4a.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,225 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 00:58 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,250 | $19.74 | $44,415.00 |
DisclosureSEC source: 0001209191-20-051388 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,125 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 23:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-20-012520 · doc1.xml · derivative · entry 4 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 23:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $124.00 | $1,860,000.00 |
DisclosureSEC source: 0001567619-20-012520 · doc1.xml · nonDerivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,402 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 23:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $63.10 | $946,500.00 |
DisclosureSEC source: 0001567619-20-012520 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| April 30, 2020 Filed Jun 23, 2020 23:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 338 | $62.59 | $21,154.07 |
DisclosureSEC source: 0001567619-20-012520 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,402 F1 · date: Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 23:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,407 | $79.98 | $192,511.86 |
DisclosureSEC source: 0001567619-20-007786 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,064 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 00:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,537 | $82.00 | $126,034.00 |
DisclosureSEC source: 0001567619-20-007469 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,471 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 00:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,618 | $78.47 | $126,964.46 |
DisclosureSEC source: 0001567619-20-007062 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,008 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| March 24, 2020 Filed Mar 27, 2020 00:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,041 | $74.36 | $151,768.76 |
DisclosureSEC source: 0001567619-20-007062 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,626 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 20, 2019. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 00:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,599 | $73.05 | $262,906.95 |
DisclosureSEC source: 0001567619-20-006964 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,667 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 29,590 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001567619-20-006626 · doc1.xml · derivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,590 Underlying: Common Stock · 29,590 shares Expires 2030-03-15 F2 · date: Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006626 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,266 F1 · price: Restricted stock units granted on March 16, 2020. Price not applicable. Read SEC document |
| March 13, 2020 Filed Mar 18, 2020 01:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,644 | $84.50 | $645,918.00 |
DisclosureSEC source: 0001567619-20-006626 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,886 Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 02:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005673 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,530 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2019 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2020, 2021 and 2022, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F4 · balance_after: On June 7, 2019, the reporting person filed a Form 4 which inadvertently over reported the total amount of securities beneficially owned by the reporting person by 50 shares. This Form 4 corrects such error by decreasing the total amount of securities beneficially owned by the reporting person by such 50 shares. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 23:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,375 | $18.06 | $42,892.50 |
DisclosureSEC source: 0001209191-19-051407 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,375 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 13,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-19-051041 · doc4.xml · derivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-09-24 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2019. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051041 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,750 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 25, 2019. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 22:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,250 | $20.24 | $45,540.00 |
DisclosureSEC source: 0001209191-19-050587 · doc4.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 14,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012953 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,635 F1 · price: Restricted stock units granted on June 5, 2019. Price not applicable. Read SEC document |
| April 30, 2019 Filed Jun 7, 2019 23:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001567619-19-013104 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,994 F1 · date: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 21:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,656 | $89.18 | $326,024.90 |
DisclosureSEC source: 0001567619-19-007734 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,475 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $88.73 to $89.68. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 22, 2019 Filed Mar 27, 2019 00:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,598 | $88.05 | $316,803.90 |
DisclosureSEC source: 0001567619-19-007692 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,131 Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 21:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,930 | $90.47 | $174,614.24 |
DisclosureSEC source: 0001567619-19-007573 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,729 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $90.11 to $90.80. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 21:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,589 | $89.62 | $232,019.71 |
DisclosureSEC source: 0001567619-19-007573 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,659 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $89.09 to $90.08. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 21:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,728 | $93.07 | $346,964.96 |
DisclosureSEC source: 0001567619-19-007383 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,248 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $92.87 to $93.41. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 23,450 | $0.00 Strike: $94.53 | $0.00 |
DisclosureSEC source: 0001567619-19-007243 · doc1.xml · derivative · entry 3 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 Underlying: Common Stock · 23,450 shares Expires 2029-03-14 F2 · date: Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007243 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,976 F1 · price: Restricted stock units granted on March 15, 2019. Price not applicable. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,169 | $94.53 | $677,685.57 |
DisclosureSEC source: 0001567619-19-007243 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,606 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 917 | $94.76 | $86,894.92 |
DisclosureSEC source: 0001567619-19-006234 · doc1.xml · nonDerivative · entry 2 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,775 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-006234 · doc1.xml · nonDerivative · entry 1 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,692 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 9,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-18-006564 · doc1.xml · derivative · entry 6 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 9,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F6 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 600 | $94.35 | $56,610.96 |
DisclosureSEC source: 0001567619-18-006564 · doc1.xml · nonDerivative · entry 5 Ajer Jeffrey Robert · CIK 0001557533 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,135 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F5 · price: The price in column 4 is the weighted average price. The price actually received ranged from $94.13 to $94.66. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.